Chemist + Druggist is part of Pharma Intelligence UK Limited
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Having Problems? Get in Touch
This copy is for your personal, non-commercial use. Please do not redistribute without permission.
Printed By
Pharmacy bodies have voiced disappointment that a Public Health England (PHE) review “fails” to offer guidance on how to mitigate the higher COVID-19 risks for BAME people.
“Evidence suggests that COVID-19 may have a disproportionate impact on people from Black, Asian and minority ethnic (BAME) groups”, according to the PHE review, Disparities
| Table |
|---|
Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst
Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.
All fields are required.
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.
What do you make of the PHE report?